Stock Ratings / Health Care / CRON / options

TRLV (58) RGC (38) TLRY (32) OBIO (28) ⌘ Pro Terminal →

Cronos Group Inc. Common Share (CRON) Options Positioning, Max Pain & Unusual Sweeps

$3.36 +0.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Cronos Group Inc. Common Share (CRON) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.24B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-2.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRON)Realized 20D OHLCV Swing Band: ±5.6%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±5.6%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (CRON)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for CRON.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRON)

✓Walkthrough of CRON's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRON // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +25.84%⚡ TESTING RESISTANCE

2026-10-30O $3.35H $3.36L $3.27C $3.36VOL 1.09M

RES: $3.44SUP: $3.27SMA50: $3.30SMA200: $2.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRON Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRON Butterfly Map → + Track CRON →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +24.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRON today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRON. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRON today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRON)

Health Care Rank #318 of 1016 ⚔️ TRLV vs CRON Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRON vs. TRLV, RGC, TLRY, OBIO)

Industry: Medicinal Chemicals and Botanical Products (24 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Cronos Group Inc. Common Share (CRON) ranks #318 by composite RQD confidence (52/100, grade D+) and #334 by equity capitalization ($1.24B). Within this direct 5-issuer industry benchmark cohort, CRON leads on earnings valuation at N/A trailing P/E, while TRLV leads on capital efficiency and profitability with 12.8% ROIC and 60.2% gross margin. TRLV currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with CRON at 52/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRON ACTIVE Cronos Group Inc. Common Share	D+	52/100	—	42.8%	-4.5%	+0.30%	$1.24B	Benchmark Subject
TRLV Trulieve Cannabis Corp. Subordinate Voting Shares	D+	58/100	—	60.2%	12.8%	-0.19%	$2.04B	/trlv-vs-cron →
RGC Regencell Bioscience Holdings Limited	D-	38/100	—	—	—	-5.64%	$3.40B	/rgc-vs-cron →
TLRY Tilray Brands Inc.	E	32/100	—	28.4%	-3.9%	-1.86%	$390.2M	/tlry-vs-cron →
OBIO Orchestra BioMed Holdings Inc.	E	28/100	—	96.0%	-35.0%	+1.67%	$366.0M	/obio-vs-cron →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001656472

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cronos Group Inc. Common Share (CRON) reported GAAP revenue of $146.6M (+24.6% vs. FY2024 revenue of $117.6M , and +68.0% cumulative change since FY2023) , GAAP net income of -$2.9M, operating cash flow of $25.9M, and free cash flow of $149.0K (-97.7% YoY). On the balance sheet, CRON closed FY2025 with $1.20B in total assets against $0 in total debt (Altman Z-Score: 15.20, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$146.6M	-$2.9M	$25.9M	$149.0K	$1.20B	—
FY2024 (FY)	2024-12-31	$117.6M	$40.0M	$18.8M	$6.4M	$1.17B	—
FY2023 (FY)	2023-12-31	$87.2M	-$73.9M	-$42.8M	-$42.8M	—	—

3. CRON Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRON stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Cronos Group Inc. Common Share (NASDAQ: CRON) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $3.36 (+0.30% 1D, market cap $1.24B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRON ranks #318 in composite RQD confidence.

How does CRON compare to TRLV and RGC in the Health Care sector?

Within the Health Care sector (Medicinal Chemicals and Botanical Products), CRON carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of 42.8%, and ROIC of -4.5%. By comparison, TRLV (Trulieve Cannabis Corp. Subordinate Voting Shares) holds a D+ grade (58/100 RQD, P/E N/A, ROIC 12.8%, cap $2.04B) and RGC (Regencell Bioscience Holdings Limited) posts a D- grade (38/100 RQD, P/E N/A, ROIC —, cap $3.40B). Among the 5-stock peer group, CRON leads on earnings multiple (N/A) while TRLV leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRON?

Per CRON's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001656472), Cronos Group Inc. Common Share generated $146.6M in revenue (+24.6% YoY), -$2.9M in net income, and $149.0K in free cash flow against $1.20B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRON trading relative to its 50-day, 200-day, and 52-week technical levels?

CRON last traded at $3.36 (+0.30% on volume of 666,408 shares), positioning the stock +1.82% above its 50-day simple moving average ($3.30) and +17.89% above its 200-day simple moving average ($2.85). Across its 52-week range of $2.28 to $3.61, CRON sits at the 81.2% percentile with a 14-day RSI of 50.4 (NEUTRAL RANGE) and an implied next-earnings move of ±5.6% ($3.17 to $3.55).

CRON Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is CRON's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for CRON.

Direct Sub-Reports: CRON RQD Cockpit CRON 12M Forecast CRON Earnings & Move CRON Dividends & DRIP CRON Insiders & 13F CRON Whale Options CRON Profit Sankey CRON News & Why